Zentek (TSE:ZEN) has released an update.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Zentek Ltd. has been granted a second patent from the Canadian Intellectual Property Office for their novel antimicrobial agent used in ZenGUARD™, potentially impacting medical and veterinary markets. The patented compound has shown high efficacy in fighting bacteria, fungi, and viruses, with ongoing research to expand its applications. The company aims to leverage this development to enhance shareholder value as part of their broader intellectual property commercialization strategy.
For further insights into TSE:ZEN stock, check out TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue